IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A heterocyclic compound represented by the formula I:



. . . (I)

wherein

X represents nitrogen atom or CH;

Y represents C_1-C_6 alkyl;

R_1 represents morpholino (which may be substituted with one to four C_1-C_6 alkyl); and

R_2 and R_3 each independently represent hydrogen atom or C_1-C_6 alkyl.

Claims 2-6 (Cancelled)

Claim 7 (Previously Presented): The compound of claim 1, wherein X is N.

Claim 8 (Previously Presented): The compound of claim 1, wherein X is CH.

Claim 9 (Previously Presented): The compound of claim 1, wherein Y is methyl.

Claim 10 (Previously Presented): The compound of claim 1, wherein Y is ethyl.

Claim 11 (Previously Presented): The compound of claim 1, wherein Y is n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl or n-hexyl.

Claim 12 (Previously Presented): The compound of claim 1 wherein R_1 is morpholino that is not substituted.

Claim 13 (Previously Presented): The compound of claim 1 wherein R_1 is morpholino that is substituted with one to four C_1-C_6 alkyl groups.

Claim 14 (Previously Presented): The compound of claim 1, wherein R_2 and R_3 are each hydrogen.

Claim 15 (Previously Presented): The compound of claim 1, wherein only one of R_2 and R_3 is hydrogen.

Claim 16 (Previously Presented): The compound of claim 1, wherein R_2 and R_3 are each C_1-C_6 alkyl.

Claim 17 (Previously Presented): The compound of claim 1, wherein X is CH, Y is methyl, R_1 is morpholino, and R_2 and R_3 are each methyl.

Claim 18 (Previously Presented): The compound of claim 1 that is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine.

Claim 19 (Previously Presented): The compound of claim 1 that is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholinopyrimidine.

Claim 20 (Previously Presented): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 21 (Previously Presented): A method for inhibiting the growth of a cancer cell comprising contacting the cancer cell with an effective amount of the compound of claim 1.

Claim 22 (Currently Amended): The method of claim 21, wherein said ~~tumor~~ cancer cell is human tumor cell.

Claim 23 (Currently Amended): The method of claim 22, wherein said ~~tumor~~ cancer cell is part of a solid human tumor.

Claim 24 (Currently Amended): The method of claim 23, wherein said contacting occurs *in vivo*.

Claim 25 (Previously Presented): The method of claim 24, wherein said cancer cell is a human colon cancer cell, a human lung cancer cell, a human breast cancer cell, or a human prostate cancer cell.